Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
4(80.0%)
Phase 1
1(20.0%)
5Total
N/A(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07228156Not ApplicableEnrolling By Invitation

Study to Evaluate Xtresse Serum in Individuals With Thinning Hair

Role: lead

NCT07482423Phase 1Not Yet Recruiting

XVIE to Treat Androgenetic Alopecia (AGA)

Role: lead

NCT07224555Not ApplicableEnrolling By Invitation

Study Evaluating Xtressé Gummy Supplement in Women With Self-Perceived Thinning Hair

Role: lead

NCT07221773Not ApplicableEnrolling By Invitation

Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair

Role: lead

NCT07041489Not ApplicableRecruiting

Evaluating the Combined Use of Supplement and Serum in Promoting Hair Growth in Women With Self-perceived Thinning Hair

Role: collaborator

All 5 trials loaded